Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-167-3 | CAS number: 513-77-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: LD50 = 1690 mg/kg bw
Acute dermal toxicity: derogation statement included; according to SIAR 2008 an LD50 >1895 mg/kg was stated in the NIAR report 2008 (based on barium carbonate)
Acute inhalation toxicity: data waiving
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1983
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP-compliant guideline study with the following deviations: - According to the guideline, healthy young adults should be used. The age of the rats was missing in this report. - The analytical purity of the test substance is not indicated in the report.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- (Adopted: 12 May 1981)
- Deviations:
- yes
- Remarks:
- (see rational for reliability)
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. A. Ivanovas, 7964 Kisslegg/Allgäu
- Age at study initiation: Not reported
- Weight at study initiation: Males: 100-125 g; Females: 100-115 g
- Housing: Group housing of five animals per sex per cage in labelled Makrolon cages (type III) containing sawdust bedding material (Fa. Brandenburg, 2849 Goldenstedt-Arkeburg).
- Diet (ad libitum except overnight prior to and approx. 4 hours after dosing): Pelleted rodent diet (Ssniff R10 pellets, Ssniff Versuchstierdiäten, 4770 Soest/Westf.
- Water (ad libitum): Tap water
- Acclimation period: 5 days before start of treatment
ENVIRONMENTAL CONDITIONS
Animals were housed in a controlled environment.
- Temperature: ca. 20°C
- Relative humidity: 40 - 60 %
- Air changes: Approx. 10 air changes per hour
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 1%
- pH value of suspensions: 10
MAXIMUM DOSE VOLUME APPLIED: 5.0 ml/kg
The control animals received the vehicle alone. - Doses:
- 1470 mg/kg, 1780 mg/kg, 2150 mg/kg
- No. of animals per sex per dose:
- 5 male / 5 female
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: On the day of dosing animals were observed for signs of reaction to treatment at frequent intervals. On subsequent days animals were observed at leaste once daily. Individual bodyweights were recorded on the day of dosing and on days 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight - Statistics:
- The acute oral median lethal dose (LD50) based on the mortality rate (x/n) during 14 days after dosing was calculated using the method of Finney (1971), Probit Analysis (3rd Edition) Cambridge University Press.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 690 mg/kg bw
- 95% CL:
- 1 060 - 2 010
- Mortality:
- Mortalities occured within 72 hours after dosing.
Number of dead males per dose:
Control: 0/5
1470 mg/kg: 2/5
1780 mg/kg: 4/5
2150 mg/kg: 4/5
Number of dead females per dose:
Control: 0/5
1470 mg/kg: 1/5
1780 mg/kg: 2/5
2150 mg/kg: 4/5 - Clinical signs:
- other: Slight pilo-erection was observed in the control animals on the day of dosing. Clinical signs observed on the day of dosing in rats treated with bariumcarbonate included pilo-erection, hunched posture, pallor of extremities, abnormal gait (waddling), incr
- Gross pathology:
- Autopsy mainly revealed congestion of liver and and inflammation of the glandular region of the stomach in rats that died during the study.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Based on the results of this study, an LD50 of 1690 mg/kg bw has been calculated for males and females for BaCO3.
- Executive summary:
In a GLP compliant acute oral toxicity study, performed according to OECD guideline 401, the test item BaCO3 was administered to groups of 5 male and 5 female Sprague Dawley rats at dose levels of 1470, 1780 and 2150 mg/kg body weight.
Mortalities occurred within 72 hours after dosing. Signs of reaction to treatment included pilo-erection, hunched posture, pallor of extremities, abnormal gait (waddling), increased or decreased respiratory rate, laboured respiration, diarrhoea, chromodakryorrhoea, decreased motility and loss of righting reflex. Complete recovery was evident in surviving animals by day 3 as judged by external appearance and behaviour.
Autopsy mainly revealed congestion of liver and inflammation of the glandular region of the stomach in rats that died during the study.
Body weight gain was poor in the surviving male rat of the highest dose group (2150 mg/kg) and one female rat of the mid-dose group (1780 mg/kg).
In conclusion, the LD50 of BaCO3 is calculated to be 1690 mg/kg body weight by oral route in the rat.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 690 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute toxicity, oral:
A reliable acute oral toxicity study with BaCO3 (Müller, 1983) results in an LD50 of 1690 mg/kg for males and females. Based on the results of this study, it was concluded that BaCO3 requires a classification and labelling as "acute tox 4"; H302 (harmful if swallowed) according to GHS.
Acute toxicity, dermal:
The toxicity of barium carbonate and barium chloride may reasonably be considered to be determined by availability of Ba2+cations. As a first surrogate for bioavailability, the water solubility of a test substance may be used. Barium carbonate is poorly soluble in water whereas barium chloride is well water soluble.Read-across from soluble to the poorly soluble barium compound is considered acceptable because toxicokinetic data on the poorly soluble barium carbonate indicates a markedly lesser bioavailability than the soluble barium chloride. However, it is to be concluded that this read-across will likely lead to rather conservative no-effect levels.
Annex VIII, point 8.5 of Regulation No 1907/2006 specifies that information on the acute toxicity of substances shall be provided according to the relevant exposure routes. According to point 8.5.3, column 2, testing by the dermal route is appropriate if (1) inhalation of the substance is unlikely, and (2) skin contact in production and/or use is likely, and physicochemical and toxicological properties suggest potential for a significant rate of absorption through the skin. For barium carbonate, inhalation can be anticipated. Therefore, provision (1) of point 8.5.3 is not fulfilled. However, according to the SIAR, an acute dermal toxicity study on barium chloride was conducted under OECD TG 402 in compliance with GLP: in this study, the dermal LD50was greater than 2000 mg/kg bw in rats. Nevertheless, the primary source for this study is not available: the SIAR refers to a NIER report dated 2008.
Acute toxicity, inhalation:
A pre-test was performed to develop a design for generating a stable testing atmosphere. However, based on the technical properties of barium carbonate, the performance of an acute inhalation toxicity test is neither technically feasible nor scientifically relevant for this type of compound. Due to (i) the particle size which is much larger than the pestled substance used for the pre-study, (ii) the low mobility and (iii) the negligible volatility of barium carbonate, the test material can safely be assumed to have a very low potential for human inhalation hazard during handling or application.
Justification for classification or non-classification
Acute oral toxicity
In a reliable GLP study performed to OECD Guideline 401 (Müller, 1983), barium carbonate was administered by gavage at 1470, 1780 and 2150 mg/kg bw to 5 male and 5 female rats (Sprague-Dawley). The animals were observed for clinical signs and mortality for 14 days. male The study results in an LD50 of 1690 mg/kg bw and therefore it was concluded that BaCO3 requires a classification and labelling as "acute tox 4"; H302 (harmful if swallowed) according to GHS. The classification as 'harmful' is supported by read-across with BaCl2
Specific target organ toxicant (STOT) – single exposure: oral
The classification criteria according to regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral are not met since no reversible or irreversible adverse health effects were observed immediately or delayed after exposure and no effects were observed at the guidance value, oral for a Category 1 classification of 300 mg/kg bw and at the guidance value, oral for a Category 2 classification of 2000 mg/kg bw in addition to this effects which were responsible for the death of the animals. No classification required.
Acute dermal toxicity
According to the SIAR 27 prepared for barium chloride, an acute dermal toxicity study on barium chloride was conducted according to OECD TG 402, in compliance with GLP. In this study, the dermal LD50 was greater than 2000 mg BaCl2/kg bw in rats. It is note here that the primary data could not be made available to the registrant but using the secondary information no classification according to regulation (EC) 1272/2008 will be necessary for barium carbonate (LD50 >1895 mg/kg bw.). For argumentation on read across please refer to the discussion above.
Acute inhalation toxicity
Based on the technical properties of barium carbonate, the performance of an acute inhalation toxicity test is neither technically feasible nor scientifically relevant for this type of compound. Due to the MMAD/GSD and the particle size which are much higher than the pestled substance used for the pre-study, the low mobility and the negligible volatility of barium carbonate, the test material can safely be assumed to have a very low potential for human inhalation hazard during handling or application. No classification is required according to regulation (EC) 1272/2008.
Specific target organ toxicant (STOT) – single exposure: inhalation
The classification criteria according to regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, inhalation are not met since the performance of an acute inhalation toxicity test is neither technically feasible nor scientifically relevant for this type of compound.
The test material can safely be assumed to have a very low potential for human inhalation hazard during handling or application. No effects are expected at the guidance value, inhalation for a Category 1 classification of <= 1 mg/L/4h and at the guidance value, oral for a Category 2 <= 5 mg/L/4h - > 1 mg/L/4h. No additional classification required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
